Close Update: Wall Street Trades Lower on Worries About iPhone X Sales

Close Update: Wall Street Trades Lower on Worries About iPhone X Sales

Stocks closed mostly lower on Tuesday with selling pressure on component stock Apple ( AAPL ) dragging down the entire technology sector and leaving the Nasdaq at its lowest level in six days. Investors bailed out of the tech giant amid concerns that sluggish iPhone X sales will permeate its suppliers with the semiconductor sector losing 1% in the aftermath.

Losses for the Dow and S&P 500 were mitigated, however, by gains in the retail and energy sectors on the back of record holiday sales, and possible supply disruptions from a major Libyan oil pipeline. Brent crude oil futures set a two-and-a-half year high following a deliberate explosion at the Es Sider pipeline that could slash supply from Libya by roughly 90,000 barrels per day.

On the economic front, home prices continued to appreciate according to a monthly survey by Case Shiller with gains in certain regions outstripping income advances.

A pair of regional manufacturing indices were mixed. The Richmond Fed manufacturing index fell 10 points to 20.0 in December, a larger-than-expected decline.

But the Dallas Fed manufacturing index improved by more than 10 points to 29.7 in December, an almost 12-year high in the index.

Here’s where the markets stood at the close:


Dow Jones Industrial Index was down 7.85 points (-0.03%)

S&P 500 was down 2.84 points (-0.11%)

Nasdaq Composite Index was down 23.71 points (-0.34%)


FTSE 100 was closed

Nikkei 225 was down 0.20%

Hang Seng Index was closed

Shanghai China Composite Index was up 0.78%


(+) TEUM (+120.87%) Adds support for blockchain technology in its billing and settlement services

(+) IGC (+90.65%) Plans to use blockchain to address issues specific to medical cannabis industry

(+) DMPI (+32.53%) Gets fast track designation for brain tumor drug candidate

(+) APTO (+29.78%) Gets orphan drug designation for leukemia treatment candidate


(-) LTEA (-20.13%) Enters into convertible debt facility to fund change in business focus

(-) PTLA (-10.68%) FDA to extend review of AndexXa biologic by 90 days to May 2018

(-) FLWS (-3.96%) Downgraded at Northcoast to neutral from buy

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

Related posts